Causes of IgD myeloma deaths in MRC/UKRI myeloma clinical trials
| IgD myeloma deaths . | Old trials (n = 44), n (%) . | Recent trials (n = 70), n (%) . | P . |
|---|---|---|---|
| All deaths | 44 (100) | 43 (61) | |
| Progressive disease | 21 (48) | 21 (49) | 0.99 |
| Infection | 1 (2) | 8 (19) | 0.01 |
| Renal failure | 3 (7) | 4 (9) | 0.7 |
| Cardiac/respiratory disease | 5 (11) | 3 (7) | 0.7 |
| Malignancy other than myeloma | 1 (2) | 1 (2) | 0.99 |
| Other causes | 13 (29) | 6 (14) | 0.12 |
| Early mortality (all causes within 100 d of trial entry) | 9 (20) | 3 (4) | 0.01 |
| IgD myeloma deaths . | Old trials (n = 44), n (%) . | Recent trials (n = 70), n (%) . | P . |
|---|---|---|---|
| All deaths | 44 (100) | 43 (61) | |
| Progressive disease | 21 (48) | 21 (49) | 0.99 |
| Infection | 1 (2) | 8 (19) | 0.01 |
| Renal failure | 3 (7) | 4 (9) | 0.7 |
| Cardiac/respiratory disease | 5 (11) | 3 (7) | 0.7 |
| Malignancy other than myeloma | 1 (2) | 1 (2) | 0.99 |
| Other causes | 13 (29) | 6 (14) | 0.12 |
| Early mortality (all causes within 100 d of trial entry) | 9 (20) | 3 (4) | 0.01 |